Cited by 595Cardiac, Anesthesia and Surgical OutcomesLipoproteins and Cardiovascular HealthCardiac and Coronary Surgery Techniques

Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial

Open access
Durazzo, Anai E.S, Machado, Fábio S, Ikeoka, Dimas T, De Bernoche, Cláudia, Monachini, Maristela C, Puech-Leão, Pedro, Caramelli, Bruno·2004·Journal of Vascular Surgery

Abstract

Objectives This prospective, randomized, placebo-controlled, double-blind clinical trial was performed to analyze the effect of atorvastatin compared with placebo on the occurrence of a 6-month composite of cardiovascular events after vascular surgery. Cardiovascular complications are the most important cause of perioperative morbidity and mortality among patients undergoing vascular surgery. Statin therapy may reduce perioperative cardiac events through stabilization of coronary plaques.Methods One hundred patients were randomly assigned to receive 20 mg atorvastatin or placebo once a day for 45 days, irrespective of their serum cholesterol concentration. Vascular surgery was performed on average 30 days after randomization, and patients were prospectively followed up over 6 months. The cardiovascular events studied were death from cardiac cause, nonfatal myocardial infarction, unstable angina, and stroke.Results Fifty patients received atorvastatin, and 50 received placebo. During the 6-month follow-up primary end points occurred in 17 patients, 4 in the atorvastatin group and 13 in the placebo group. The incidence of cardiac events was more than three times higher with placebo (26.0%) compared with atorvastatin (8.0%; P =.031). The risk for an event was compared between the groups with the Kaplan-Meier method, as event-free survival after vascular surgery. Patients given atorvastatin exhibited a significant decrease in the rate of cardiac events, compared with the placebo group, within 6 months after vascular surgery (P =.018).Conclusion Short-term treatment with atorvastatin significantly reduces the incidence of major adverse cardiovascular events after vascular surgery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jvs.2004.01.004

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The adverse lipid effects of immunosuppressive drugs differ between drugs.

    “These effects vary with different immunosuppressive drugs [497,498,502-506].”
  • Immunosuppressive drug regimens can adversely affect lipid metabolism, raising total cholesterol, VLDL, triglycerides, and LDL particle size and density.

    “Immunosuppressive drug regimens may have adverse effects on lipid metabolism leading to increases in TC, VLDL, and TGs, and in the size and density of LDL particles.”
  • These dyslipidaemias increase the risk of atherosclerotic cardiovascular disease and transplant arterial vasculopathy in transplant recipients.

    “Dyslipidaemias are very common in patients who have undergone heart, lung, liver, kidney, or allogenic haematopoietic stem cell transplantation, and predispose such patients to an increased risk of developing ASCVD and transplant arterial vasculopathy [497-501].”
  • Dyslipidaemias are very common in recipients of heart, lung, liver, kidney, or blood-forming stem cell transplants.

    “Dyslipidaemias are very common in patients who have undergone heart, lung, liver, kidney, or allogenic haematopoietic stem cell transplantation, and predispose such patients to an increased risk of developing ASCVD and transplant arterial vasculopathy [497-501].”
  • In an RCT, atorvastatin 20 mg versus placebo significantly reduced the composite endpoint of cardiac death, MI, stroke, and unstable angina in 100 patients undergoing vascular non-cardiac surgery including abdominal aortic aneurysm repair.

    “In an RCT comparing atorvastatin 20 mg with placebo, the composite endpoint of cardiac death, MI, stroke, and unstable angina was significantly reduced in 100 patients undergoing vascular non-cardiac surgery, including abdominal aortic aneurysm repair.208”

    From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [208]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 34 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease (4S). Lancet 1994;344:1383-9.
  2. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in coronary syndromes: a randomized controlled trial. JAMA 2001;285:1758-60.
  3. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF III, Graor RA, et al. Coronary artery disease in peripheral vascular patients: a classification of 1000 coronary angiograms and results of surgical man- agement. Ann Surg 1984;199:223-33.

Cited by

Sorted by citations

Authors
Durazzo, A. E. S., Machado, F. S., Ikeoka, D. T., De Bernoche, C., Monachini, M. C., Puech-Leão, P., & Caramelli, B.
Affiliations
Universidade de São Paulo (BR)
Corresponding author
Durazzo, Anai E.S
Venue
Journal of Vascular Surgery
Publisher
Elsevier BV
Published
2004-05
Volume
39
Issue
5
Pages
967-975
ISSN
0741-5214 (ISSN-L)
OpenAlex
W2030475349
Cited by
595
References
34
Citations by year
2026: 4 · 2025: 3 · 2024: 12 · 2023: 11 · 2022: 6 · 2021: 15 · 2020: 19 · 2019: 11 · 2018: 17 · 2017: 18 · 2016: 27 · 2015: 23 · 2014: 36 · 2013: 27 · 2012: 33
FWCI
33.54
Type
journal article
Language
en
Open access
Locations
  • Journal of Vascular Surgery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Fundação de Amparo à Pesquisa do Estado de São Paulo
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac, Anesthesia and Surgical Outcomes
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cardiac and Coronary Surgery Techniques
Keywords
atorvastatin, vascular surgery, perioperative cardiovascular events, statin therapy, myocardial infarction, unstable angina, stroke, cardiac mortality, event-free survival
MeSH terms
Atorvastatin, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Patient Compliance, Postoperative Complications, Prospective Studies, Pyrroles, Risk Factors, Time Factors, Vascular Surgical Procedures, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review